ArticleAnalytical methods : advancing methods and applications2025
Development and validation of a novel LC-MS/MS method for simultaneous quantification of alvocidib and its glucuronide: application to pharmacokinetic and tissue distribution study in rats.
Article in Analytical methods : advancing methods and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Alvocidib, an approved drug for the treatment of acute myeloid leukemia, undergoes glucuronidation metabolism. The purpose of this study is to develop a robust and sensitive LC-MS/MS method to simultaneously quantify alvocidib and its metabolite, alvocidib-glucuronide (Alv-G), and apply this method in a pharmacokinetic and tissue distribution study in rats. A UHPLC system coupled to an AB Sciex QTrap 4000 triple quadrupole mass spectrometer was used for the analysis. The analytes were separated using a Biphenyl column with 0.1% formic acid in water and acetonitrile as the mobile phases and were quantified under positive electrospray ionization (ESI) mode using a multiple reaction monitoring (MRM) approach. Protein precipitation with acetonitrile was used in sample processing. The method showed a good linearity within the range of 2.4-5000.00 nM for both analytes. The method was reproducible, with intra and inter-day accuracy and precision ranging from 84-98% and <13% respectively. The extraction recovery and matrix effect achieved acceptable ranges (82-105%). Stability studies demonstrated that they were stable under bench-top (91-99%), freeze-thaw (83-110%), and long-term storage conditions (80-106%). The PK results showed that after oral administration of alvocidib, both alvocidib and Alv-G were detected in plasma with the parent drug showing highest distribution in the colon, and lowest in the small intestine. In contrast, Alv-G showed the highest distribution in the small intestine and the lowest amount in the colon compared to the other tissues. This method is applicable for PK and tissue distribution studies to quantify both alvocidib and its glucuronide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.